sporin A; CD34-selected peripheral blood stem cell transplantation Induction of autologous graft-versus-host disease (GVHD) following autologous stem cell transplantation (SCT) has been a potent therapeutic modality for patients with a variety of diseases, including hematologic malignancies and breast cancer. Autologous GVHD can be induced by the administration of cyclosporin A (CsA) for a limited period following autologous SCT. [1] [2] [3] [4] [5] [6] This autoaggression syndrome shares similar dermal pathology with acute GVHD after allogeneic SCT. The therapeutic benefits are not only derived from the high dose of chemotherapy or irradiation used in the preparative regimen, but also from the eradication of residual tumor cells by the autoreactive T lymphocytes.
The induction of autologous GVHD is a two-tiered process requiring both the active inhibition of the thymicdependent clonal deletion of autoreactive T cells and the elimination of a peripheral immunoregulatory system by the preparative regimen providing a permissive environment for the autoreactive T cells to manifest autoaggression. [2] [3] [4] Moreover, reconstitution of the immunoregulatory system limits the course of autoaggressive disease. A vigorous cellular immune reaction, dominated by the proliferation of activated autoreactive CD8 + cytotoxic T lymphocytes, is mounted during autologous GVHD. [6] [7] [8] [9] These CD8 + autoreactive T cells lyse a variety of tumor cell lines derived from patients with myeloma, lymphoma and breast cancer. 7, 8 The antitumor effect of this autoaggression syndrome can be enhanced by administration of interferon (IFN)-g, by upregulating the major histocompatibility complex (MHC) class II target antigen on the tumor cells. 10, 11 Several clinical trials in patients with hematologic malignancies suggest that the induction of autologous GVHD can reduce relapse rate. [12] [13] [14] [15] Disease-free survival among lymphoma patients who develop autologous GVHD is higher than in those who do not develop this autoaggression syndrome. 14, 15 Autologous GVHD can be induced in 70-80% of autologous bone marrow (BM) recipients by administration of CsA in the early post autologous SCT period. 3, 12 This autoaggression syndrome can also be induced in recipients of peripheral blood stem cells (PBSCs) using the same regimen after transplantation. 16 However, the incidence of autologous GVHD after peripheral blood stem cell transplantation (PBSCT) was markedly lower compared to the incidence following bone marrow transplantation (BMT). 15, 17 Several reasons were postulated to account for the reduced incidence of autologous GVHD in recipients who received PBSCs, including the infusion of a large number of T cells and monocytes that may downregulate the development of autologous GVHD. 17, 18 Administration of CsA following CD34-selected PBSCT may be more likely to induce autologous GVHD than transplantation of unmanipulated PBSC, since it does not accompany infusion of T cells and monocytes. The resultant autoimmune attack against autologous tumor cells may prevent relapse of malignant lymphoma. In the present study, five non-Hodgkin's lymphoma (NHL) patients, whose leukapheresis products were likely to be contaminated by lymphoma cells, were treated with PBSCT using selected CD34 + cells in order to not only induce autologous GVHD but also to purge malignant clonogenic cells. Clinical evidence of autologous GVHD appeared in three of five patients. Results from the current trial demonstrate an increased frequency of autologous GVHD in patients treated with CsA and IFN-g following CD34-selected PBSCT.
Patients and methods

Patients
Between March 1997 and March 2000, five patients with NHL underwent transplantation with CD34-selected PBSCs, followed by administration of CsA and IFN-g. Among them, three patients had chemotherapy-resistant follicular lymphoma; the other two had aggressive diffuse lymphoma with BM involvement. The median age was 50 years (range 46-56 years). Normal renal, cardiac, pulmonary and hematopoietic reserves, in addition to an ECOG performance status of 0 to 1, were required for all patients. PBMCs of five patients collected at the recovery phase using the Isolex50t magnetic cell separation device (Baxter Immunotherapy, Irvine, CA, USA). The minimum number of CD34 + cells was 1.5 Â 10 6 /kg. The mean yield and purity of CD34 + cells after separation were 64.3 and 96.2%, respectively ( Table 2 ). The CD34 + cells were cryopreserved until use and the remaining PBSCs were cryopreserved to rescue against graft failure.
Preparative regimens and induction of autologous GVHD
Two patients underwent conditioning before autologous SCT with high-dose chemotherapy consisting of ramimustine (200 mg/m 2 i.v. days À8 and À3), carboplatin (300 mg/ m 2 i.v. days À7, À6, À5 and À4), etoposide (500 mg/m 2 i.v. days À6, À5 and À4) and cyclophosphamide (50 mg/kg i.v. days À3 and À2). The remaining three patients received a conditioning regimen consisting of cyclophosphamide (50 mg/kg i.v. days À3 and À2) and fractionated total body irradiation at 3 Gy daily for 4 days (total 12 Gy) in combination with cytarabine (4 g/m 2 i.v. days À4 and À3) for patient no. 3 or etoposide (15 mg/kg i.v. days À4 and À3) for patient no. 5.
CsA (2.5 mg/kg/day) was administered intravenously to the patients from days 1 to 21 following transplantation. Recombinant IFN-g (100 mg/m 2 ; Shionogi, Osaka, Japan) was administered subcutaneously to all patients on days 7, 14, 21 and 28. G-CSF (5 mg/kg/day) was given to these patients from day 1 until the leukocyte count exceeded 5.0 Â 10 9 /l. This treatment protocol was reviewed and approved by the institutional review board and informed consent was obtained from all patients.
Cytotoxicity assay
In order to monitor the appearance of autoreactive T cells, cytotoxicity of PBMCs against autologous lymphocytes was assessed in four patients at different time points following PBSCT. Heparinized PB was drawn from the patients prior to conditioning chemotherapy. PBMCs were separated using density-gradient centrifugation, suspended in RPMI 1640 (Gibco, Grand Island, NY, USA), and cryopreserved at -801C after aliquoting. When testing the autocytotoxic activity of the post transplant lymphocytes, pretransplant PBMCs were thawed and cultured in the Cr (400-1200 Ci/g chromium, Dupont NEN Products, Boston, MA, USA) for 1 h. After washing with phosphate-buffered saline, 10 4 cells were cocultured with 8 Â 10 5 autologous PBMC that were obtained following PBSCT. After 4 h of incubation, 51 Cr release was assessed and the percent-specific lysis (mean7s.e.) was determined from triplicate cultures as previously described. 8 
Statistical analysis
Complete remission (CR) was defined as the disappearance of all measurable or evaluable disease for at least 12 weeks after transplantation. Partial remission (PR) was defined as a 50% or more reduction in the product of bidimensional lesion measurements at all sites of measurable disease. Data were analyzed on September 1, 2002.
Results
Autocytotoxic activity of lymphocytes after PBSCT
Cytotoxicity of PBMCs against autologous lymphocytes was detectable in four of four patients evaluated. Figure 1 illustrates the changes in autocytotoxic activity of PBMCs over time after transplantation. Lymphocytes with autocytotoxic activity appeared as early as day 14, and remained detectable until day 36. Peak cytotoxicity was observed between days 18 and 24. Such autocytotoxic lymphocytes were not detectable in another patient after PBSCT who did not receive CsA and IFN-g (Figure 1 E) .
Hematologic recovery and treatment-related toxicity after PBSCT Table 3 summarizes the hematologic recovery and treatment-related toxicity after CD34-selected PBSCT among the five patients. Although platelet recovery was slightly delayed, the day of last platelet transfusion was not postponed. All patients demonstrated rapid recovery of hematopoiesis comparable to patients transplanted with unmanipulated PBSC grafts. There was no increase in infectious complications related to transplantation of selected CD34 + cells followed by the administration of CsA. Toxicity related to the administration of IFN-g was not observed except for transient fever on the day of injection.
Development of autologous GVHD
Although patients no. 1 and 3 did not manifest any signs of GVHD, three patients developed clinical evidence of autologous GVHD. Patient no. 5 experienced not only skin but also gut and liver GVHD (Figure 2 ). The level of serum concentrations of alkaline phosphatase (627 IU/l, normal range 114-394) and total bilirubin (1.6 mg/dl, normal range o1.0) increased, and diarrhea developed (1.5 l/day) concurrently with leukocyte recovery on day 15 Table 3 Hematologic and biochemistry parameters following peripheral blood stem cell transplantation (Figure 3) . Erythema gradually faded after day 28 and disappeared spontaneously by day 35. PBSCT. Patient no. 4 is in continuous CR after 57 months. At a median follow-up time of 52.6 months, the disease-free survival rate of all patients was 60%. None of the three patients who developed autologous GVHD had experienced relapse. Examination of [ 18 F] 2-fluoro-d-2-deoxyglucose (FDG)-positron emission tomography (PET) demonstrates no recurrence in three of these patients.
Response and survival
Discussion
Administration of CsA and IFN-g following CD34-selected PBSCT is well tolerated without additional toxicity. The brevity of the follow-up period in this limited trial makes the effects on disease relapse impossible to ascertain. Longterm survival, however, appears to be enhanced in patients who developed autologous GVHD and the results achieved are worthy of further exploration.
The immune modulation explored in this trial reflects many years of laboratory investigation into autologous GVHD. Autologous GVHD is a two-tiered process requiring both active inhibition of the thymic-dependent clonal deletion of autoreactive T cells and the elimination of immunoregulatory cells. In the normal process of thymocytes differentiation, autoreactive T cells that interact with thymic epithelial cells undergo apoptosis. 19, 20 Administration of CsA blocks this process and the autoreactive T cells are released into the periphery. 21, 22 The release of autoreactive T cells into the periphery is not by itself sufficient to induce autologous GVHD because of peripheral autoregulatory mechanisms. 9, 23 Autoregulatory functions that inhibit autoreactive T cells need to be depleted by high-dose chemotherapy or total body irradiation.
Several recent studies suggest that the ability to induce autologous GVHD by CsA treatment may be compromised in patients receiving PBSCT compared to patients receiving autologous BMT. 15, 17 In a pilot study, autologous GVHD was not induced in six patients receiving unmanipulated PBSC grafts, despite the use of a relatively high dose of CsA (2.5 mg/kg/day) and IFN-g. 15 Comparatively, clinical evidence of autologous GVHD including the development of a generalized erythematous rash compatible with autologous GVHD appeared in three of five patients transplanted with CD34-selected PBSCs. Autologous SCT using CD34 + cells selected from the BM or PBSC products have been successfully used for treatment of advanced malignancies such as NHL. 24, 25 Among the histologic subtypes of NHL, follicular lymphoma is likely to infiltrate BM with lymphoma cells often detected in the marrow, even in the early stage of the disease. 26, 27 Thus, high-dose chemoradiotherapy combined with transplantation of CD34-selected PBSC has been utilized to treat patients with follicular lymphoma. 28 On the other hand, because diffuse lymphoma with BM involvement often includes metastatic spread into extranodal sites from the early stage of its clinical course, high-dose chemotherapy with autologous SCT may be unsuccessful. Furthermore, leukapheresis products may be contaminated by lymphoma cells and patients with BM involvement require enrichment of CD34 + cells in order to eliminate or reduce contamination of the stem product cell grafts by lymphoma.
Successful induction of autologous GVHD after CD34-selected PBSCT supports the hypothesis that the leukapheresis products may contain a large number of regulatory cells that can inhibit development of autologous GVHD. Of interest, studies in the animal system suggest that transfer of mature T cells along with stem cell products can modify the ability to induce autologous GVHD. [29] [30] [31] In addition, PBSCs used in this current study were mobilized with high-dose chemotherapy and G-CSF. Previous studies suggest that the leukapheresis products of normal individuals receiving G-CSF contain approximately 50 times more monocytes and 10 times more T cells than do typical BM grafts, both of which are capable of inhibiting T-celldependent proliferative responses against alloantigens. 32, 33 In this regard, rigorous T-cell deletion of PBSC products may also lead to occurrence of autologous GVHD in the absence of CsA treatment. 34 Although the mechanism of autologous GVHD remains unclear, it is possible that regulatory cells in the PBSC graft may also inhibit the autoreactive T cells that mediate autologous GVHD. Further studies are clearly needed in a large number of patients undergoing CD34-selected PBSCT to evaluate the potential role of immunoregulation.
Although the treatment outcome of NHL has greatly improved during the past two decades, treatment of follicular lymphoma and high-risk aggressive lymphoma still remains problematic. Even high-dose radiochemotherapy in combination with PBSCT may not improve survival of patients with follicular lymphoma. 35 Recent studies by Schultze et al 36 and Dorfman et al 37 suggest that follicular lymphoma cells could be targets of autologous cytotoxic T cells. The induction of autoreactive T cells associated with autologous GVHD may be effective in targeting residual tumor cells, preventing the relapse of follicular lymphoma. Further investigation of CD34-selected PBSC transplantation followed by administration of CsA and low-dose IFN-g, a safe and less cumbersome therapeutic modality, is warranted to improve the treatment outcome of follicular lymphoma or diffuse lymphoma with BM involvement. A randomized trial with molecular flow cytometry data is necessary to assess efficacy on MRD, relapse and survival.
